Geron Corporation Licenses Antigen Targeting Patents For Cancer Vaccine Program From Immunomic Therapeutics

MENLO PARK, Calif., & GAITHERSBURG, Md.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) and Immunomic Therapeutics Inc. (ITI) announced today a patent license agreement under which Geron will receive exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines.